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Background: Intravascular Brachytherapy as a tool to reduce restenosis is thought to alter vascular wall
biology and vessel wall protein function. Platelet accumulation is also indeed important in the genesis of
restenosis.
We examine the in vitro effects of beta-radiation on the certain vessel wall extra cellular matrix proteins. We
hypothesized that vessel wall (proteins) had become less prone to thrombosis.
Methods:We examined platelet adhesion to 20-Gy beta radiation treated extra cellular matrix proteins under
ﬂow conditions. Platelet ﬂow adhesion was evaluated or quantiﬁed by image analysis, aggregation size
analysis using theWatershed program and real-time ﬂuorescence images of thrombus formation. The effect of
beta radiation on vWF was further showing by measuring the binding of domain-speciﬁc antibodies to
radiation treated vWF.
Results: 20-Gy beta radiation signiﬁcantly decreased platelet adhesion to extra cellular matrix protein; vWF
and collagen Type III and had no effect on the adhesion upon ﬁbrinogen and ﬁbronectin. The beta-radiation
affected mostly the AI, A2 and A3 domains of the vWF molecule on the surface, whereas the D′–D3 and B–C1
domains on the surface remain unaffected and suggesting a signiﬁcant decrease in vWF binding capacity to
the GPIb, heparin and collagen ligands.
Conclusion: Beta radiation treatment can alter the reactivity of the certain vessel wall extra cellular matrix
proteins, in particular vWF and collagen. The vessel wall may become less prone to platelet adhesion, which
results in decrease thrombus formation. It might help to reduce the onset of acute coronary occlusion after the
intervention.
© 2010 Elsevier Ireland Ltd. Open access under the Elsevier OA license.1. Introduction
Exciting results from the trials of anti-proliferatives drug-eluting
stents have resulted in a decrease of instant restenosis [1,2]. Intravas-
cular Brachytherapy (IVBT) is still a safe and effective method of
prevention of restenosis [3–6]. It has been shown to be favorable in
comparison to placebo. IVBT has been recognized as a treatment
modality for reducing coronary restenosis after angioplasty and stent-
implantation procedures [7–10]. Single doses in excess of 7–56 Gynd factor; IVBT, Intravascular
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ibutions in writing this article.
e Elsevier OA license.intracoronary catheter-based beta-radiations have clearly shown a
reduction the genesis of restenosis in the animal and clinical models
[11,12].
After vascular injury, the ﬁrst occurring step is the adherence of
platelets to the endotheliumand the exposedmedia [13]. As endothelial
denudation the platelet adhesion has been observed both by light and
scanning electron microscopy after arterial intimal damage and
restenosis [14]. Jaster et al have shown that platelet activation during
brachytherapy is not caused by irradiation but by the procedure of
catheter based VBT [15]. However, their experiments did not study the
effect of radiation on the thrombogenicity of the vessel wall. We
developed in our laboratory an in vitro ﬂow system [16–27] to mimic
the effects of beta radiation and study of platelet adhesion to endothelial
extra cellular matrix proteins. We have reported platelet adhesion to
photodynamic therapy (PDT)-treated matrix proteins before [20]. The
PDT reduces platelet adhesion to vWF and ﬁbrinogen. In contrast,
284 Y.P. Wu et al. / International Journal of Cardiology 156 (2012) 283–288collagen becomes increasingly prone to platelet adhesion [20]. Here we
have studiedhowbeta radiation alters the reactivity of the certain vessel
wall proteins for platelets.
2. Methods
In our vitro experiments, we coat endothelial extra cellular matrix protein vWF,
collagen, ﬁbrinogen and ﬁbronectin to glass coverslip by incubation or air-pressure
spraying procedure. The interactions between platelet and these proteins are further
determined by a blood perfusion system. The ﬂow studies were performed in a well-
deﬁned perfusion chamber, which could be reversible sealing of the coverslip to
chamber [17,23–25]. A syringe pump was used to aspirate the blood through the
coverslip at desired ﬂow rates in the chamber. Both coverslips were perfused in
sequence in a random order, thus exposing the control and beta-radiation coverslips to
the same blood ﬂow. After perfusion, the coverslips were removed, rinsed, ﬁxed,
dehydrated and stained with the May–Grunwald–Giemsa. Platelet adhesion to the
coverslip was measured with light microscopy coupled to an image analyzer system.
The randomly selected coverslip areas were evaluated. Platelet adhesion was expressed
as the percentage of the surface covered with platelets. The platelet adhesion to
collagen type III induced aggregate under ﬂow conditions. The aggregation size was
evaluated by a morphological analytic program. Another ﬂow chamber was mounted
on an inverted-stage Real-time ﬂuorescence microscope. It was suitable for very low
light levels and used to visualize directly platelet adhesion and subsequent platelet
aggregation, throughout the perfusion period. As platelet adhesion to collagen type III
at a shear rate of 1600 s−1 was almost completely dependent on vWF, [21] we reasoned
that a major damage of beta-radiation was through modiﬁcation of vWF. So to further
study, we performed an ELISA on the normal vWF surface and the beta radiation-
treated vWF surface with different domain speciﬁc monoclonal antibodies [20].
2.1. The human endothelial extra cellular matrix protein preparation
VWF was prepared from cryoprecipitate using polyethyleneglycol precipitation
and gel ﬁltration. Fibronectin was prepared by afﬁnity chromatography from citrated
plasma [21,22]. Fibrinogen (Enzyme Research Labs, USA) was further puriﬁed by size
exclusion chromatography on Sepharose 4B. Placenta collagen type III was purchased
from Sigma Chemical Co.
2.2. Coverslips coating
Coverslips were cleaned overnight in a chromium trioxide solution, rinsed with
distilled water and coated by 10 μg/ml vWF or 100 μg/ml ﬁbrinogen for 1 h. Each
coverslip was then incubated in 1% human albumin to prevent non-speciﬁc protein
binding.
For ﬁbronectin and collagen coating, spraying technique was done with a
retouching airbrush (Badger model 100, IL USA). After the spraying procedure, the
coverslips were also incubated for 60 min with 1% human albumin to prevent non-
speciﬁc protein binding.
2.3. Beta-32P radiation application for the coverslips, which coated by extra cellular matrix
proteins
Beta-32P radiation application for the coverslips is performedwith an intracoronary
centered balloon catheter (Galileo intravascular radiotherapy system, TX USA) [28]. In
summary, it consists of four components: 1, the source delivery unit; 2, the centering
catheter; 3, the 32P source wire and 4, the inactive wire. The longitudinal distance of the
‘full’ prescribed dose (100% isodose) coverage, measured by radio chromic ﬁlms, does
about 22 mm constitute the effective radiation length [28,29].
The coverslips, coated with vWF, collagen type III, ﬁbronectin, and ﬁbrinogen, were
irradiated in a special coverslip bracket. A beta-32P radiation dose of 20 Gy was used in
all experiments. The irradiation time is automatically calculated and controlled by
Galileo intravascular radiotherapy system instrument.
2.4. Platelet perfusion procedure
The perfusion studies were performed in a well-deﬁned perfusion chamber, which
could be reversible sealing of the coverslip to chamber by vacuum force [23–25]. A
syringe pumpwas used to aspirate the blood through the coverslip at desired ﬂow rates
in the chamber. Both coverslips were perfused in sequence in a random order, thus
exposing the control and beta-radiation coverslips to the same blood ﬂow.
Blood used for platelet perfusion studies was collected from healthy donors
receiving no medication. For vWF and ﬁbrinogen perfusion experiments, blood was
anticoagulant 1:10 vol/vol with 110 mM trisodium citrate (pH 7.4). For collagen
perfusions, blood was anticoagulant with 1: 10 vol/vol 200 U/ml low molecular weight
heparin (Fragmin, Sweden) [25]. The temperature of whole blood was kept on 37 °C.
Perfusions were performed at the optimal shear rate for a difference of coated proteins.
300 s−1 for ﬁbrinogen and ﬁbronectin, 1000 s−1 for vWF and 1600 s−1 for collagen
[22,26,27,30,31].2.5. Evaluation of platelet adhesion
After perfusion, the coverslips were removed, rinsed, ﬁxed in 0.5% glutaraldehyde,
dehydrated in methanol and stained with the May–Grunwald–Giemsa. Platelet
adhesion to the coverslip was measured with light microscopy coupled to an image
analyzer system (Optimas 6.0 the Netherlands). Thirty randomly selected coverslip
areas were evaluated, and the results from triplicate coverslips were averaged. Platelet
adhesion was expressed as the percentage of the surface covered with platelets.
2.6. The aggregation size analysis, using Watershed program
The platelet adhesion to collagen type III induced really aggregate under ﬂow
conditions. The aggregation size was analyzed by the Watershed program provided by
the Optima software [24,32]. The Watershed technique separates conﬂuent or
overlapping objects based on color intensity levels. This technique was reproducible
with a variation coefﬁcient of 9.8%. Platelet aggregation size on collagen type III surface
was subdivided into 6 groups; [1] contact and spread platelet with an area of b 8 μm2,
[2] aggregated with an area between 8–40 μm2, [3] aggregated with an area between
40–200 μm2, [4] aggregated with an area between 200–400 μm2, [5] aggregated with an
area between 400–600 μm2, [6] aggregated with an area N600 μm2.
2.7. Real-time ﬂuorescence images of thrombus formation
The ﬂow chamber was mounted on an inverted-stage microscope equipped with
an epiﬂuorescent illumination and a Pioneer DVD-recorder (Fig. 1). It was suitable for
very low light levels and used to visualize directly platelet adhesion and subsequent
platelet aggregation, throughout the perfusion period. Whole blood was labeled by
mepacrine (Sigma), warmed to 37 °C, aspirated through this chamber. The perfusion
images were recorded with a time interval of 80 ms and automatically evaluated.
2.8. An ELISA study of control vWF surface and beta radiation-treated vWF surface with
domain speciﬁc monoclonal antibodies
We performed an ELISA on the normal vWF surface and the beta radiation-treated
vWF surface with domain speciﬁc monoclonal antibodies.
20 Gy beta-radiation treated vWF coverslip and control coverslip were incubated
with monoclonal antibodies directed against speciﬁc domains of the vWF molecule
(RAG-35, 40, RU-1, RU-5, antiD′–D3, and vWF9) or polyclonal antibody. Then the
antibody binding upon vWF was quantiﬁed as follows: coverslips were incubating for
1 h with the peroxidase-labeled anti-mouse or rabbit antibody and coloring with H2O2-
phenylenediamine (OPD) buffer. Coloring was stopped by 3 N H2SO4. The optical
density was measured at 492 nm. Results were expressed as the percentage of the
control.
2.9. The vWF domain speciﬁc monoclonal antibodies made by our laboratory
Recombinant A2, A3, D′–D3 of human vWF, was expressed and puriﬁed. To further
delineate how beta-radiation affected the vWF protein, antibodies, which directed
against speciﬁc vWF domain, were made in our laboratory, Utrecht. Monoclonal
antibody RU1 directed against the A2 repeat, monoclonal antibody RU5 directed
against the A3 repeat and a polyclonal rabbit antibody directed against the D′–D3
region were prepared in our laboratory. For production of monoclonal antibody RU1
and RU5 (IgG2a,k) hybridoma cells were injected in mice, and ascites was collected. IgG
was puriﬁed on a protein G-Sepharose column, and Fab fragments were generated
using an ImmunoPure-Fab kit (Pierce, Rockford, IL). RU5-Fab was further puriﬁed with
afﬁnity chromatography in our laboratory Utrecht.
2.10. Other vWF domains speciﬁc monoclonal antibodies
Monoclonal Antibody RAG-35, directed against the A1 domain, is a generous gift of
Dr. van Mourik, (Sanquin research, Amsterdam, Netherlands). RAG-40, which directed
against the D4 domain, is also a gift of Dr. vanMourik. vWF9, which inhibits interactions
between VWF and GPIIbIIIa or αvβ3, is a generous gift of dr. Denis, (INSERM U143, Le
Kremlin-Bicetre, France;). Polyclonal anti-vWF peroxides labeled antibody was
obtained from Dako Co, Denmark.
2.11. Statistical analysis
All perfusions were performed in triplicate for each condition. The results are
presented as the mean from experiments with blood from 3 different donors, unless
indicated otherwise. One-way Analysis of Variance (ANOVA) and Tukey–Kramer
Multiple Comparisons Test evaluation included calculation of mean values, standard
error and nonparametric test for comparison of every two groups. All reported P values
are two-sided. P values below 0.05 were considered to indicate statistical signiﬁcance.
All analyses were performed with the use of GraphPad, Prism and Instat software (San
Diego USA.).
Fig. 1. Vacuum-chamber study in real-time for platelet adhesion The vacuum-chamber contained a blood inlet [1], blood outlet [2], a vacuum channel connected [3], warm water
inlet [4] and warmwater outlet [5]. On the top of the chamber, a silicone rubber gasket (yellow) was placed. A hole was cut in this silicon sheet to create a perfusion slit, as shown by
red color area (slit width: 10 or 2 mm; length: 3 cm; height = thickness of sheet: 0.125 μm) connecting the blood inlet 1 and blood outlet 2. On both sides, next to the ﬂow area, two
slits were cut in the silicon sheet to obtain vacuum compartments (as shown by blue color). The coverslip, shown by grey color, was leak-proof, reversible sealing onto a silicone
sheet by vacuum force. A syringe pump was used to aspirate the blood through the coverslip at desired ﬂow rates in the chamber. Both coverslips were perfused in sequence in a
random order, thus exposing the control and beta-radiation coverslips to the same blood ﬂow.
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3.1. Beta-radiation treatment signiﬁcantly decreased platelet adhesion to
vWF and collagen type III and had no effect to adhesion upon ﬁbrinogen
and ﬁbronectin
Beta-radiation treatment signiﬁcantly decreased platelet adhesion
in compared to controls for vWF (40.5±1.9% vs13.4±3.2%;
P=0.0184) and collagen type III (46.3±3.0% vs10.6±1.3%;
P=0.0086) (Fig. 2). Beta-radiation had no effect on platelet adhesion
to ﬁbrinogen (29.0±3.1% vs. 27.9±0.3%; P=0.7658) and ﬁbronectin
(22.4±2.0% vs. 14.9±2.3%; P=0.1334) (Fig. 2).3.2. The decreased platelet adhesion coverage on beta-radiation
treatment collagen was associated with a smaller thrombi presented
The platelet adhesion to collagen type III showed aggregates. The
morphological aggregation size was evaluated with the Watershed
program, the Optima software. The results are expressed as a
percentage of the total coverage present in a certain aggregation
size class and presented in the Table 1 and Fig. 3.
Platelet aggregation size on collagen type III surface was subdivided
into 6 groups; [1] contact and spread platelet with an area of b8 μm2, [2]
aggregatedwith an area between 8–40 μm2, [3] aggregatedwith an area
between 40–200 μm2, [4] aggregated with an area between 200–
400 μm2, [5] aggregated with an area between 400–600 μm2, [6]
aggregated with an area N600 μm2.
It showed that bigger thrombi present on control collagen type III
surface and the smaller thrombi presented on beta-radiation treated
collagen type III surface.3.3. Real time ﬂuorescence labeling platelet adhesion recording and
analysis
The adhesion to vWF and collagen type III was greatly diminished
after beta radiation-treatment. The analysis (the movie presentation
ﬁles are in the Supplementary Appendix) showed that in the very ﬁrst
step of platelet adhesion, the ﬁrst touchdown of a platelet on the surface
was diminished. Furthermore, the distance overwhich the platelets roll
over collagen type III or vWF to reach a full stop was diminished. This
would indicate beta-radiation decreased the reactivity of collagen and
vWF, resulting in decreased platelet adhesion.3.4. An ELISA study of beta radiation-treated vWF surface with domain
speciﬁc monoclonal antibodies
The recognitions on the surfaces by anti-A1 and A2 domain
antibodies were completely lost (22.4% of control and 17.9% of
control, respectively). While, The recognition on the surfaces by anti-
A3 domain antibody was partly reduced (66.1% of control). The
recognitions on the surfaces by anti-D′3, D4 and B–C1–C2 domain
antibodies were same compared with control (82.9%, 81.2 and 91.7%
of control, respectively). These results showed that beta-radiation
affects, mostly the AI, A2 and A3 domains of the vWF molecule on the
surface, whereas the D′–D3 and B–C1 domains on the surface remain
unaffected. And it suggests a signiﬁcant decrease in binding capacity
of the GPIb, heparin and collagen ligands upon beta radiation-treated
(the ligands bindings on the vWF surface have been indicated in
Fig. 4).
4. Discussion
It is well known that after intracoronary balloon catheter, there is
eradication of the endothelial cell layer and, thus, exposure of the sub-
endothelial protein, such as collagen and vWF. After the initial step of
adhesion, platelets become activated, resulting in platelet-platelet
interaction leading to aggregation formation [33]. The current study
demonstrates that beta-radiation treatment alters the reactivity of a
certain vessel wall extra cellular matrix proteins, in particular, vWF and
collagen. It signiﬁcantly decreased platelet adhesion to vWF and
collagen type III but had no effect on adhesion to ﬁbrinogen and
ﬁbronectin. The decreased platelet adhesion coverage to collagen was
associated with smaller thrombi. These in vitro results offer an
explanation the low thrombogenicity of vessels after beta-radiation.
Because platelet accumulation is indeed important in the genesis of
restenosis,we reasoned that the extra cellularmatrix protein denatured
under beta-radiation might help reduce the onset of acute coronary
events and of in the genesis of restenosis. In addition, the growth factor
released by activated platelet, stimulated the proliferation of smooth
muscle cells, which may be an inﬂuential factor in the restenosis [34].
At higher shear rates, the interaction between vWF in the vesselwall
and platelet glycoprotein GPIb is essential to allow platelet adhesion.
Before vWF can interact with GPIb, it should be ﬁrst bind to collagens
present in the vessel wall [35]. Depending on the differences of the
vessels, collagen content ranges from 20% in the aorta wall 35 to 40% in
the smaller arteries and it is evenhigher in the venousvascularwall [31].
Here we show that after beta-radiation treatment platelet adhesion is
Fig. 2. Effects of beta-radiation on platelet adhesion to collagen type III, vWF, Fibronectin and Fibrinogen Beta radiation-treated and control coverslips were perfused in a single pass
perfusion chamber, using a shear rate of 300 s−1 (Fibrinogen, Fibronectin) 1000 s−1 (vWF) or 1600 s−1 (CT3) for 5 min. Values are sowed by mean and standard error of the mean.
The light gray bar graphs indicate the data from controls, and the dark gray bar graphs indicate the data from beta radiation-treated samples. Coverslips were stained with May–
Grunwald–Giemsa. Adhesion to untreated collagen type III (panel A) was homogenous, with aggregates. Platelet adhesion to beta-radiation treated collagen type III (panel B) was
decreased signiﬁcantly, with few aggregates. Adhesion to untreated vWF (panel C) was homogenous, with few spreading. Platelet adhesion to beta-radiation treated vWF (panel D)
was decreased signiﬁcantly, without spreading platelets.
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multiple roles of the vWFmolecule in platelet adhesion,we investigated
how it affects its different functional domainsof vWF (Fig. 4). The results
of these experiments clearly demonstrate that after radiation, there is
impaired antibody-binding capacity to the A-type domains. Apparently,
the A domain had lost their proper conformation. Both the A1 domainTable 1
Aggregation size analysis for platelet adhesion to collagen type III Aggregation size was
evaluated with the Watershed program of the Optima software (version 6.51.199) and
subdivided. The results are expressed as a percentage of the total coverage present in a
certain aggregation size class.
Aggregation
size class (μm2)
% of total coverage
Control Beta radiation
b8 0.1 0.9
8–40 0.8 6.2
40–200 9.7 36.1
200–400 10.4 22.3
400–600 15.4 15.3
N600 63.7 19.2and the A3 domain contain a disulphide bridge that is important for the
stabilization of their three-dimensional conformation. Although not
proven, it is tempting to speculate that these disulphide bridges are
oxidized. The recognition on the surface by antibodies recognizing
domains A1 and A2 were completely lost (22.4% of control and 17.9% of
control, respectively), while the antibody recognizing domain A3 on the
surface was partly reduced (66.1% of control). The loss of recognition by
an antibody, that can recognize the binding site within vWF for the
platelet receptor GPIb clearly indicates a reduced binding capacity to the
platelet membrane GPlb receptor. Although the evidence provided is
indirect, it could explain the decreased platelet adhesion to vWF found
after beta-radiation. The A3-domain of vWF on the surface contains the
collagen-binding site, and beta-radiation might also result in reduced
capacity of vWF to bind to collagen. Of interestwas the fact that the B-Cl
domain (platelet GPIIbllIa-binding site) was largely unaffected by beta
radiation. As the domains A1, A2 and A3 are important in platelet
adhesion/ aggregation and followed the onset of restenosis.
Wehave reportedplatelet adhesion tophotodynamic therapy (PDT)-
treated extra cellular matrix proteins before [20]. The PDT reduces vWF
and ﬁbrinogen capacity for thrombus formation and resulting in
decreased platelet adhesion. However, collagen becomes increasingly
prone to thrombosis after PDT. In contrast, the beta-radiation treatment
Fig. 4. Beta-radiation treated/vWF coated coverslip and control coverslip were
incubated with monoclonal antibodies directed against speciﬁc domains of the vWF
molecule. The recognitions of beta-radiation treated vWF by anti-A1 and anti-A2
antibodies were completely lost, while the antibody recognizing domain A3 was partly
reduced. The ligands bindings on the vWF surface have been indicated here.
Fig. 3. Effect of beta-radiation on aggregation size of platelet adhesion to collagen type
III. Morphological aggregation size analysis by stained with theMay–Grunwald–Giemsa
and watershed program for platelet adhesion to collagen type III showed that bigger
thrombi present on control collagen type III surface and the smaller thrombi presented
on beta-radiation treated collagen type III surface.
287Y.P. Wu et al. / International Journal of Cardiology 156 (2012) 283–288decreased the reactivity of the certain vessel wall extra cellular matrix
proteins, in particular, vWF and collagen.
5. Limitations
The biology of radiation effects is different from the effects produced
by in vitro or in vivo study. The typical effect of radiation is DNAdamage
in various cell types, includingendothelial cells, smoothmuscle cells and
ﬁbroblasts, dependingon the radiationpenetrationdepth into the vessel
wall. In our study, the vessels were not inﬂuenced by all these factors.
We plan study of these effects by our in vitro experimental model and
something molecular mechanisms by which balloon angioplasty IVBT
affect NF-kappaB, ICAM-1 and VCAM-1 etc. [36].
Furthermore, we should study in vivo blood ﬂow inside the human
vessel to conﬁrm our experimental results from in vitro ﬂow
condition utilized in this study.6. Conclusion
Beta radiation treatment can alter the reactivity of the certain vessel
wall extra cellular matrix proteins, in particular, vWF and collagen. The
vesselwallmay become less prone to thrombosis, resulting in decreased
platelet adhesion and aggregation. It might help to reduce the onset of
acute coronary occlusion after the intervention.
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